» Articles » PMID: 30109228

Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects

Overview
Date 2018 Aug 16
PMID 30109228
Citations 133
Authors
Affiliations
Soon will be listed here.
Abstract

Bone fractures and segmental bone defects are a significant source of patient morbidity and place a staggering economic burden on the healthcare system. The annual cost of treating bone defects in the US has been estimated to be $5 billion, while enormous costs are spent on bone grafts for bone injuries, tumors, and other pathologies associated with defective fracture healing. Autologous bone grafts represent the gold standard for the treatment of bone defects. However, they are associated with variable clinical outcomes, postsurgical morbidity, especially at the donor site, and increased surgical costs. In an effort to circumvent these limitations, tissue engineering and cell-based therapies have been proposed as alternatives to induce and promote bone repair. This review focuses on the recent advances in bone tissue engineering (BTE), specifically looking at its role in treating delayed fracture healing (non-unions) and the resulting segmental bone defects. Herein we discuss: (1) the processes of endochondral and intramembranous bone formation; (2) the role of stem cells, looking specifically at mesenchymal (MSC), embryonic (ESC), and induced pluripotent (iPSC) stem cells as viable building blocks to engineer bone implants; (3) the biomaterials used to direct tissue growth, with a focus on ceramic, biodegradable polymers, and composite materials; (4) the growth factors and molecular signals used to induce differentiation of stem cells into the osteoblastic lineage, which ultimately leads to active bone formation; and (5) the mechanical stimulation protocols used to maintain the integrity of the bone repair and their role in successful cell engraftment. Finally, a couple clinical scenarios are presented (non-unions and avascular necrosis-AVN), to illustrate how novel cell-based therapy approaches can be used. A thorough understanding of tissue engineering and cell-based therapies may allow for better incorporation of these potential therapeutic approaches in bone defects allowing for proper bone repair and regeneration.

Citing Articles

Synergistic influences of BMP9 and NGF on the osteogenic differentiation of C3H10T1/2 mesenchymal stem cells.

Liu J, Yang K, Li G, Tan Y J Orthop Surg Res. 2025; 20(1):287.

PMID: 40089726 DOI: 10.1186/s13018-025-05669-4.


A Procedural Overview of the Involvement of Small Molecules in the Nervous System in the Regulation of Bone Healing.

Wei X, Li M, You J, Luo J, Zhai J, Zhang J Int J Nanomedicine. 2025; 20:1263-1284.

PMID: 39906525 PMC: 11792627. DOI: 10.2147/IJN.S505677.


The impact of graphene quantum dots on osteogenesis potential of Wharton's jelly mesenchymal stem cells in fibrin hydrogel scaffolds.

Khazaeel K, Sadeghi A, Khademi Moghaddam F, Mohammadi T Cytotechnology. 2024; 77(1):14.

PMID: 39665046 PMC: 11628478. DOI: 10.1007/s10616-024-00672-9.


Engineered Osteochondral Scaffolds with Bioactive Cartilage Zone for Enhanced Articular Cartilage Regeneration.

Golebiowska A, Intravaia J, Sathe V, Kumbar S, Nukavarapu S Ann Biomed Eng. 2024; 53(3):597-611.

PMID: 39602036 PMC: 11835937. DOI: 10.1007/s10439-024-03655-1.


Establishment of immortalized rabbit bone marrow mesenchymal stem cells and a preliminary study of their osteogenic differentiation capability.

Zhang Y, Xu C, Huang Y, Tan D, Luo W, Zhang Y Animal Model Exp Med. 2024; 7(6):824-834.

PMID: 39592420 PMC: 11680476. DOI: 10.1002/ame2.12513.


References
1.
Gautam S, Dinda A, Mishra N . Fabrication and characterization of PCL/gelatin composite nanofibrous scaffold for tissue engineering applications by electrospinning method. Mater Sci Eng C Mater Biol Appl. 2013; 33(3):1228-35. DOI: 10.1016/j.msec.2012.12.015. View

2.
Cartmell S, Porter B, Garcia A, Guldberg R . Effects of medium perfusion rate on cell-seeded three-dimensional bone constructs in vitro. Tissue Eng. 2003; 9(6):1197-203. DOI: 10.1089/10763270360728107. View

3.
Berner A, Reichert J, Woodruff M, Saifzadeh S, Morris A, Epari D . Autologous vs. allogenic mesenchymal progenitor cells for the reconstruction of critical sized segmental tibial bone defects in aged sheep. Acta Biomater. 2013; 9(8):7874-84. DOI: 10.1016/j.actbio.2013.04.035. View

4.
Mont M, Carbone J, Fairbank A . Core decompression versus nonoperative management for osteonecrosis of the hip. Clin Orthop Relat Res. 1996; (324):169-78. DOI: 10.1097/00003086-199603000-00020. View

5.
Younger E, Chapman M . Morbidity at bone graft donor sites. J Orthop Trauma. 1989; 3(3):192-5. DOI: 10.1097/00005131-198909000-00002. View